regulatory
confidence high
sentiment positive
materiality 0.80
FDA grants Breakthrough Therapy designation to Nuvalent's NVL-655 for ALK+ NSCLC
Nuvalent, Inc.
- NVL-655 received FDA Breakthrough Therapy designation for ALK-positive non-small cell lung cancer.
- Designation covers patients with locally advanced or metastatic disease after two or more prior ALK TKIs.
- Breakthrough Therapy status may accelerate development and FDA review for serious conditions.
- Announcement date: May 16, 2024.